EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tenecteplase: biochemical and clot lysis activity comparisons

Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang

Frontiers in Pharmacology · 20.12.2024 · 15

DOI: 10.3389/fphar.2024.1498116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.12.2024. Verfasst von Jan Bechmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH and Co., KG, Biberach an der Riss, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke. An optimized version of alteplase, tenecteplase, has been developed by exchanging six amino acids to increase half-life, achieve higher fibrin selectivity and increase resistance to plasminogen activator inhibitor-1. Meanwhile, several products containing tenecteplase exist. The aim of this study was to compare the fibrinolytic activity and overall product quality of the 25 mg/vial presentation of tenecteplase originator Metalyse ® (Boehringer Ingelheim Pharma GmbH and Co., KG, Ingelheim, Germany) to the 16 mg/vial formulation of the tenecteplase copy Mingfule ® (CSPC Recomgen Pharmaceutical, Guangzhou, Co., Ltd.).

Methods

We have systematically analyzed and evaluated the biochemical and fibrinolytic differences between Metalyse ® and Mingfule ® using a wide range of routine quality testing assays, supplemented by mass spectrometry analysis and surface plasmon resonance assays. Additional host cell protein quantification and clot lysis testing following plasmin incubation over time were performed.

Results

Several key differences in biochemical composition and clot lysis activity were observed between the two tenecteplase variants. Versus Metalyse ® , Mingfule ® exhibited lower clot lysis activity and contained less of the two-chain form of tenecteplase. In addition, there were differences in sialic acid content, galactosylation, and fucosylation patterns, with Mingfule ® exhibiting more bi- and less tri- and tetra-antennary glycosylation, leading to a different charge and size heterogeneity profile. Furthermore, Mingfule ® displayed highly dissimilar binding to the three clearance receptors (LRP-1, ASGR, and mannose receptor) compared with Metalyse ® . Purity analysis showed that Mingfule ® contained a lower monomer content and, in contrast to Metalyse ® , substantial amounts of host cell protein.

Discussion

Taken together, these data demonstrate that the tenecteplase copy Mingfule ® has several meaningful fibrinolytic and biochemical differences compared with Metalyse ® . This raises the question of whether data from clinical studies with one of the products can be generalized for all tenecteplase variants.

Schlagwörter

Stichwörter der Autor:innen

clot lysiscopyfibrinolysisglycosylationtenecteplasethrombosis

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharma GmbH and Co., KG, Biberach an der Riss, Germany.
  • Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Bechmann, J., Schmid, I., Brand, S., Miller, F., & Zhang, C. (2024). Tenecteplase: biochemical and clot lysis activity comparisons. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1498116

Vancouver

Bechmann J, Schmid I, Brand S, Miller F, Zhang C. Tenecteplase: biochemical and clot lysis activity comparisons. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1498116

BibTeX
@article{Bechmann2024,
  author = {Bechmann, Jan and Schmid, Ira and Brand, Simone and Miller, Felix and Zhang, Chengzhi},
  title = {Tenecteplase: biochemical and clot lysis activity comparisons},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1498116}
}
Kostenlos starten →